We are live on
!
Find out more
O
OrbiMed Portfolio holdings
AUM
$5.05B
1-Year Est. Return
125.28%
This Fund
S&P 500
This Quarter
Est. Return
-2.61%
1 Year Est. Return
+125.28%
3 Year Est. Return
+334.72%
5 Year Est. Return
+344.07%
10 Year Est. Return
+2,748.76%
AUM
$10.7B
AUM Growth
-$733M
(-6.4%)
Cap. Flow
+$511M
Cap. Flow
% of AUM
4.78%
Top 10 Holdings %
Top 10 Hldgs %
33.24%
Holding
188
New
39
Increased
39
Reduced
24
Closed
30
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Edgewise Therapeutics
EWTX
|
+$452M |
| 2 |
GRCL
Gracell Biotechnologies Inc. American Depositary Shares
GRCL
|
+$186M |
| 3 |
CMMB
Chemomab Therapeutics
CMMB
|
+$128M |
| 4 |
Haemonetics
HAE
|
+$105M |
| 5 |
Disc Medicine
IRON
|
+$86.6M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Prelude Therapeutics
PRLD
|
+$369M |
| 2 |
PRVL
Prevail Therapeutics Inc. Common Stock
PRVL
|
+$319M |
| 3 |
Pfizer
PFE
|
+$133M |
| 4 |
Biogen
BIIB
|
+$121M |
| 5 |
Centene
CNC
|
+$120M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 94.88% |
| 2 | Technology | 0.12% |
| 3 | Financials | 0% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
KNTE
26
DELISTED
Kinnate Biopharma Inc. Common Stock
KNTE
| $120M | 1.12% |
3,847,929
| – | – |
|
27
DexCom
DXCM
$29.1B
| $107M | 1% |
1,189,600
+73,200
| +7% | +$6.87M |
|
|
RPTX
28
DELISTED
Repare Therapeutics
RPTX
| $105M | 0.98% |
3,426,325
| – | – |
|
29
Keros Therapeutics
KROS
$197M
| $103M | 0.97% |
1,679,417
| – | – |
|
30
Intuitive Surgical
ISRG
$127B
| $103M | 0.96% |
418,800
+80,400
| +24% | +$20.2M |
|
31
Elevance Health
ELV
$82.3B
| $103M | 0.96% |
286,600
-23,900
| -8% | -$7.69M |
|
32
Adicet Bio
ACET
$76.7M
| $94.6M | 0.88% |
452,054
+32,772
| +8% | +$7.52M |
|
|
33
Haemonetics
HAE
$3.82B
| $94.6M | 0.88% |
+852,000
| New | +$105M |
|
34
Edwards Lifesciences
EW
$49B
| $94.2M | 0.88% |
1,126,400
+100,600
| +10% | +$8.5M |
|
|
ETNB
35
DELISTED
89bio
ETNB
| $88.3M | 0.83% |
3,729,442
| – | – |
|
36
Progyny
PGNY
$2.46B
| $85.7M | 0.8% |
1,925,260
+249,760
| +15% | +$11.7M |
|
|
TERN
37
DELISTED
Terns Pharmaceuticals
TERN
| $83.4M | 0.78% |
+3,791,204
| New | +$83.1M |
|
|
IMA
38
ImageneBio Inc
IMA
$64.8M
| $82.9M | 0.78% |
+244,495
| New | +$83.7M |
|
39
Stryker
SYK
$134B
| $82.2M | 0.77% |
337,400
+102,400
| +44% | +$24.6M |
|
|
40
Disc Medicine
IRON
$2.8B
| $78.9M | 0.74% |
+194,207
| New | +$86.6M |
|
41
Aurinia Pharmaceuticals
AUPH
$1.93B
| $78.8M | 0.74% |
6,069,032
+1,315,032
| +28% | +$19.1M |
|
|
CMMB
42
Chemomab Therapeutics
CMMB
$11.4M
| $74M | 0.69% |
+644,544
| New | +$128M |
|
|
IMGN
43
DELISTED
Immunogen Inc
IMGN
| $74M | 0.69% |
9,131,822
+6,577,922
| +258% | +$53.7M |
|
|
AFIB
44
DELISTED
Acutus Medical Inc
AFIB
| $73.2M | 0.68% |
5,477,958
| – | – |
|
|
SVA
45
DELISTED
Sinovac Biotech, Ltd
SVA
| $72M | 0.67% |
2,839,500
| – | – |
|
46
CRISPR Therapeutics
CRSP
$4.64B
| $67.3M | 0.63% |
552,500
+100,700
| +22% | +$15.2M |
|
47
Ascendis Pharma A/S
ASND
$16.6B
| $65.1M | 0.61% |
505,159
+168,659
| +50% | +$25.6M |
|
|
DCPH
48
DELISTED
Deciphera Pharmaceuticals, Inc. Common Stock
DCPH
| $61.9M | 0.58% |
1,380,900
+255,200
| +23% | +$11.9M |
|
|
LOGC
49
DELISTED
LogicBio Therapeutics, Inc. Common Stock
LOGC
| $61.6M | 0.58% |
8,466,783
| – | – |
|
50
MeiraGTx Holdings
MGTX
$1.07B
| $59.2M | 0.55% |
4,102,925
| – | – |
|
Similar funds
HSA
NL
BPWM
LFG
JIM
CTC
PAMP
SGM
OrbiMed's Q1 2021 Portfolio in Review
As of Q1 2021, OrbiMed held 188 positions worth $10.7B, down 6.4% from $11.4B the previous quarter. Its ten largest holdings account for 33% of the portfolio.
OrbiMed deployed $511M of net new capital in Q1 2021, opening 39 new positions and adding to 39 existing holdings. Its largest new stake was Edgewise Therapeutics: 13,944,680 shares worth $453M.
By sector, the portfolio is most concentrated in Healthcare at 95% of assets, down from 98% a quarter earlier, followed by Technology and Financials.
On the sell side, the largest reduction was Prelude Therapeutics, an estimated $369M trimmed.
- OrbiMed's largest Q1 2021 buy was Edgewise Therapeutics: 13,944,680 shares worth $453M.
- OrbiMed added most to Merck in Q1 2021, an estimated $83M increase.
- OrbiMed's biggest Q1 2021 reduction was Prelude Therapeutics, cutting an estimated $369M.
- OrbiMed fully exited Prevail Therapeutics Inc. Common Stock in Q1 2021, selling an estimated $319M.
- OrbiMed's ten largest holdings make up 33% of its $10.7B portfolio in Q1 2021.
- OrbiMed opened 39 new positions and closed 30 in Q1 2021.
- OrbiMed's portfolio value fell 6.4% quarter-over-quarter to $10.7B.
Based on OrbiMed's 13F filing for Q1 2021, filed 17 May 2021.